HCW Biologics Inc. Common Stock
HCWBHCW Biologics Inc. (HCWB) is a biopharmaceutical company focused on developing immunotherapy treatments utilizing natural killer (NK) cell-based platforms. The company aims to address various unmet medical needs through innovative therapies that leverage the body's immune system to target and destroy cancer cells. HCW Biologics is involved in research and development efforts to advance its pipeline of biologic products with potential applications in oncology and other therapeutic areas.
Company News
HCW Biologics showcased its lead product candidate HCW11-040, a multi-functional fusion protein combining pembrolizumab with interleukin-7, interleukin-15, and TGF-β receptor components, which demonstrates potential to expand exhausted T cells without side effects in cancer treatment.
HCW Biologics announced the selection of HCW11-040, a multi-functional fusion protein, as its lead product candidate for treating solid tumors. The immunotherapeutic combines pembrolizumab with specific cytokines and shows promising preclinical results in expanding T-cell responses without triggering cytokine storm.
HCW Biologics announced successful development of second-generation T-cell engagers targeting solid tumors, particularly pancreatic cancer and glioblastoma, with promising preclinical safety results in non-human primates and potential for treating multiple cancer types.
HCW Biologics has developed a novel pembrolizumab-based immune checkpoint inhibitor targeting solid tumors, particularly pancreatic and ovarian cancer, using its proprietary TRBC technology platform. The new immunotherapeutic shows potential to improve cancer treatment by simultaneously activating immune cells and promoting their tumor infiltrati...
HCW Biologics reported Q2 2025 financial results, highlighting a $5 million equity offering, ongoing clinical development of HCW9302 for alopecia areata, and strategic business development efforts including license agreement negotiations and T-cell engager research.
